Robert Ranney, MD
Family Medicine · Brea, CANPI 1902807670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,447 and has fallen 92.6% since, to $255 in 2024. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$848
- Pfizer$440
- Amgen$427
- GSK$353
- Novo Nordisk$348
- Merck$324
- plus $2K from 23 others
What the payments were for
- Consulting fees$200%
- Food & beverage$4,19998%
- Education$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $848 |
| Pfizer | 27 | $440 |
| Amgen | 14 | $427 |
| GSK | 16 | $353 |
| Novo Nordisk | 21 | $348 |
| Merck | 15 | $324 |
| Lilly USA, LLC | 12 | $223 |
| Boehringer Ingelheim | 10 | $207 |
| AbbVie(2 entities) | 9 | $170 |
| Kowa Pharmaceuticals America, Inc. | 6 | $160 |
| Astellas Pharma US Inc | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| AMAG Pharmaceuticals, Inc. | 4 | $75 |
| Amarin Pharma, Inc. | 3 | $66 |
| Radius Health, Inc. | 3 | $65 |
| Johnson & Johnson | 4 | $64 |
| Kaleo, Inc. | 4 | $58 |
| Therapeuticsmd, Inc. | 2 | $40 |
| Sanofi Pasteur Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Bausch Health US, LLC | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,300 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 82 | $84,476 |
| EliquisApixaban | 65 | $62,639 |
| JardianceEmpagliflozin | 38 | $55,318 |
| FarxigaDapagliflozin Propanediol | 20 | $28,921 |
| XareltoRivaroxaban | 23 | $27,616 |
| Spiriva RespimatTiotropium Bromide | 28 | $18,273 |
| OzempicSemaglutide | 15 | $17,929 |
| CreonLipase/Protease/Amylase | 12 | $15,969 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $15,190 |
| MyrbetriqMirabegron | 19 | $13,729 |
| Repatha SyringeEvolocumab | 16 | $11,484 |
| Rosuvastatin Calcium | 302 | $7,221 |
| PremarinEstrogens, Conjugated | 11 | $6,616 |
| Atorvastatin Calcium | 595 | $6,588 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $6,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $324 | $99,66798 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $207 | $73,59166 claims |
| PfizerEliquis, Premarin | $440 | $69,25576 claims |
| AstraZenecaFarxiga | $848 | $28,92120 claims |
| Johnson & JohnsonXarelto | $64 | $27,61623 claims |
| AbbVieCreon, Synthroid | $170 | $21,27062 claims |
| Novo NordiskOzempic | $348 | $17,92915 claims |
| Astellas Pharma US IncMyrbetriq | $101 | $13,72919 claims |
| GSKBreo Ellipta | $353 | $6,21613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Brea
- Dennis ShultsBrea$287K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.